Search Results
Found 2 results
510(k) Data Aggregation
(181 days)
VIVORTE BVF
Vivorté BVF™ is a moldable, self-setting, gradually resorbable, calcium phosphate bone void filler with shaped particles of human bone that contain osteoinductive demineralized bone matrix (DBM). Vivorté BVF™ is indicated for use to fill bony voids or defects of the skeletal system (i.e., extremities, pelvis) that may be surgically created or osseous defects created from traumatic injury to the bone and only for bony voids or defects that are not intrinsic to the stability of the bony structure. Vivorté BVF™ may be manually applied to the bony defect or applied to the defect through a cannula. Vivorté BVF™ is gradually resorbed and remodeled by the body as new bone formation occurs during the healing process.
Vivorté BVF™ is a moldable, self-setting, gradually resorbable, calcium phosphate bone void filler with shaped particles of human bone that contain osteoinductive demineralized bone matrix (DBM). Vivorté BVF™ is indicated for use to fill bony voids or defects of the skeletal system (i.e., extremities, pelvis) that may be surgically created or osseous defects created from traumatic injury to the bone and only for bony voids or defects that are not intrinsic to the stability of the bony structure. Vivorté BVF™ may be manually applied to the bony defect or applied to the defect through a cannula. Vivorté BVF™ isothermically hardens in vivo to form a composite of a carbonated apatite (hydroxyapatite) and shaped particles of human bone that contain DBM. Vivorté BVF™ has a compressive and bending strength that is greater than that of human cancellous bone. The carbonated apatite (hydroxyapatite) which closely resembles the mineral phase of bone provides an osteoconductive scaffold and the shaped particles of human bone contain osteoinductive demineralized bone matrix (DBM). The composite device is gradually resorbed and remodeled by the body as new bone formation occurs during the healing process. Vivorté BVF™ is provided in various kit sizes corresponding to the amount of bone void filler produced when the components of the kit are mixed together.
Each lot of allograft human bone in the Vivorté BVF™ is assayed for osteoinductive potential using an athymic mouse or rat model. The results of the osteoinductive potential testing may or may not be indicative of the osteoinductivity of Vivorté BVF™ in humans.
The provided document describes a 510(k) premarket notification for a medical device called Vivorté BVF™. A 510(k) submission generally aims to demonstrate that a new device is "substantially equivalent" to a legally marketed predicate device, rather than proving its safety and effectiveness through extensive clinical trials as would be required for a PMA (Premarket Approval). Therefore, the concept of "acceptance criteria" as applied to a device's performance in a standalone clinical efficacy study might not directly align with the information typically found in a 510(k) summary.
Based on the provided text, the Vivorté BVF™ device is claiming substantial equivalence to two predicate devices: ETEX EquivaBone® Osteoinductive Bone Graft Substitute (K090855) and Synthes® Norian® SRS® Bone Void Filler (K011897). The "study" demonstrating this substantial equivalence is primarily focused on non-clinical testing.
Here's an analysis of the provided information in response to your specific questions:
1. Table of Acceptance Criteria and Reported Device Performance
Given that this is a 510(k) submission focused on substantial equivalence, specific "acceptance criteria" for clinical performance are not explicitly detailed in the document in the way one might expect for a PMA or a de novo submission. Instead, the acceptance criteria are implicitly met by demonstrating comparable characteristics to the predicate devices through non-clinical testing.
Acceptance Criteria Category (Implied by Substantial Equivalence Basis) | Reported Device Performance (Vivorté BVF™ vs. Predicates) |
---|---|
Chemical Composition | Chemically substantially equivalent to ETEX EquivaBone® and Synthes® Norian® SRS®. Vivorté BVF™ and ETEX EquivaBone® are synthetic calcium phosphate based bone void fillers containing osteoinductive demineralized bone matrix (DBM). Vivorté BVF™ and Synthes® Norian® SRS® are composed of virtually identical synthetic calcium phosphate materials (Synthes® Norian® SRS® does not contain DBM). |
Physical Properties | Physically substantially equivalent to ETEX EquivaBone® and Synthes® Norian® SRS®. Both Vivorté BVF™ and predicate devices are intraoperatively prepared by mixing components to produce self-hardening calcium phosphate bone void fillers. Both devices have comparable mixing, handling/working, and setting times. When fully hardened, both are composed primarily of apatites with similar physical characteristics. |
Mechanical Properties | Mechanically substantially equivalent to ETEX EquivaBone® and Synthes® Norian® SRS®. Vivorté BVF™ has compressive and bending strength greater than that of human cancellous bone. When fully hardened, both are composed primarily of apatites with similar mechanical characteristics and properties. |
Resorption and Remodeling | Vivorté BVF™ is gradually resorbed and remodeled by the body as new bone formation occurs, similar to the predicate devices. |
Biocompatibility & Toxicity | Passed testing according to ISO 10993, ASTM, and USP standards. |
Sterility | Provided packaged sterile, similar to predicate devices. |
Indications for Use | Similar indications for use to the predicate devices. |
Osteoinductivity Testing (of Allograft component) | Each lot of allograft human bone in Vivorté BVF™ is assayed for osteoinductive potential using an athymic mouse or rat model. (Note: The document states these results may or may not be indicative of human osteoinductivity.) |
2. Sample Size Used for the Test Set and Data Provenance
- Test Set Sample Size: Not applicable in the context of a clinical test set for performance. The "test set" here refers to materials and animal models used for non-clinical and animal testing. Specific sample sizes for the chemical, physical, mechanical, biocompatibility, and animal testing are not provided in this summary.
- Data Provenance: The testing was performed by Vivorté, Inc. and its contractors. The country of origin for the data is implicitly the United States, where Vivorté, Inc. is located and operates. The testing is prospective in the sense that it was conducted specifically to support this 510(k) submission.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications
- Number of Experts: Not applicable. Ground truth, in the clinical sense, would be established by medical experts for patient outcomes or diagnoses. No such clinical "ground truth" establishment is mentioned as part of this 510(k) submission. For the non-clinical and animal testing, the "ground truth" is defined by established scientific and regulatory standards (e.g., ISO, ASTM, USP) and laboratory protocols.
- Qualifications of Experts: Not specified. Testers performing the non-clinical and animal studies would be qualified scientists, engineers, and veterinarians/animal technicians relevant to their fields, but their specific qualifications are not detailed.
4. Adjudication Method for the Test Set
- Adjudication Method: Not applicable. Adjudication methods (like 2+1 or 3+1) are used in clinical trials to resolve discrepancies in expert judgments for ground truth establishment. Since no clinical trials are described, this is not relevant. The "adjudication" for non-clinical tests typically involves adherence to validated methods and review by internal quality control or regulatory bodies.
5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study
- MRMC Study Done: No. An MRMC comparative effectiveness study is used to assess the impact of a device (often AI-assisted) on human reader performance in diagnostic tasks. Vivorté BVF™ is a bone void filler, not a diagnostic imaging device, and its 510(k) submission explicitly states: "Clinical testing was not necessary to determine substantial equivalence between Vivorté BVF™ and the predicate devices." Therefore, no MRMC study was conducted or is relevant.
- Effect Size of Human Readers with/without AI assistance: Not applicable.
6. Standalone Performance Study (Algorithm Only)
- Standalone Study Done: Not applicable. This question concerns the performance of an algorithm without human intervention, typically for AI/ML diagnostic devices. Vivorté BVF™ is a physical medical device, and the concept of "standalone performance" for an algorithm is not relevant. The performance of the physical device is established through the non-clinical (chemical, physical, mechanical, biocompatibility) and animal testing to show substantial equivalence.
7. Type of Ground Truth Used
- Type of Ground Truth: The "ground truth" here is based on established scientific and regulatory standards and measurement techniques for material properties (chemical composition, physical properties, mechanical strength), biocompatibility, and animal responses (for osteoinductive potential of the DBM component). It is not pathology, expert consensus on patient outcomes, or human-specific clinical outcomes data, as clinical testing was not performed.
8. Sample Size for the Training Set
- Training Set Sample Size: Not applicable. A "training set" refers to data used to train an algorithm, typically in AI/ML applications. Vivorté BVF™ is not an AI/ML device. The non-clinical and animal testing involved samples of the device and biological models for evaluation, but these are not "training sets" in the AI/ML context.
9. How the Ground Truth for the Training Set Was Established
- Ground Truth Establishment for Training Set: Not applicable, as there is no training set for an AI/ML algorithm.
Ask a specific question about this device
(111 days)
VIVORTE BVF LITE
Vivorté BVF™ Lite™ is a moldable, self-setting, gradually resorbable, calcium phosphate bone void filler. Vivorte BVF™ Lite™ is indicated for use to fill bony voids or defects of the skeletal system (i.e., extremities, pelvis) that may be surgically created or osseous defects created from traumatic injury to the bone and only for bony voids or defects that are not intrinsic to the stability of the bony structure. Vivorté BVF™ Lite™ may be manually applied to the bony defect or applied to the defect through a cannula. Vivorté BVF™ Lite™ is gradually resorbed and remodeled by the body as new bone formation occurs during the healing process.
Vivorté BVF™ Lite™ is a moldable, self-setting, gradually resorbable, biocompatible, calcium phosphate bone void filler. Vivorté BVF™ Lite™ is indicated for use to fill bony voids or defects of the skeletal system (i.e., extremities, pelvis) that may be surgically created or osseous defects created from traumatic injury to the bone and only for bony voids or defects that are not intrinsic to the stability of the bony structure. Vivorté BVF™ Lite™ may be manually applied to the bony defect or applied to the defect through a cannula. Vivorté BVF™ Lite™ isothermally hardens in vivo to form a carbonated apatite (hydroxyapatite). Vivorté BVF™ Lite™ has a compressive and bending strength that is greater than that of human cancellous bone. The carbonated apatite (hydroxyapatite), which closely resembles the mineral phase of bone, provides an osteoconductive scaffold for bone healing. The device is gradually resorbed and remodeled by the body as new bone formation occurs during the healing process. Vivorté BVF™ Lite™ is provided in various kit sizes corresponding to the amount of bone void filler produced when the components of the kit are mixed together.
The provided text describes a 510(k) submission for the Vivorté BVF™ Lite™ bone void filler, asserting its substantial equivalence to a predicate device, Synthes® Norian® SRS® Bone Void Filler. The basis for this determination is non-clinical testing, as explicitly stated that no clinical testing was performed or required. Therefore, the acceptance criteria and the study proving the device meets them are solely based on these non-clinical evaluations.
Here's an analysis based on the provided text:
1. Table of Acceptance Criteria and Reported Device Performance
The document does not explicitly list acceptance criteria as numerical thresholds but rather states that the device is "substantially equivalent" to the predicate device in various aspects. The reported performance is therefore framed in terms of similarity to the predicate.
Acceptance Criteria (Implied by Substantial Equivalence) | Reported Device Performance (Vivorté BVF™ Lite™) |
---|---|
Material Composition | Composed of synthetic calcium phosphate materials that are "virtually identical" to the predicate. Primarily composed of hydroxyapatite when fully hardened. |
Preparation and Hardening Process | Intraoperatively prepared by mixing similar components to produce a self-hardening calcium phosphate bone void filler. Isothermally hardens in vivo to form carbonated apatite (hydroxyapatite). |
Resorption and Remodeling Characteristics | Resorbed and remodeled by the body as new bone formation occurs during the healing process, similar to the predicate. Gradually resorbable. |
Mixing, Handling/Working, and Setting Times | Comparable to the predicate device. |
Chemical, Physical, and Mechanical Characteristics | Similar to the predicate device's when fully hardened (primarily hydroxyapatite). Compressive and bending strength greater than human cancellous bone. Osteoconductive scaffold for bone healing. |
Biocompatibility and Toxicity | Meets ISO 10993, ASTM, and USP standards for permanent implants, as demonstrated by testing. |
Animal Testing Performance | Demonstrated substantial equivalency to the predicate device in animal testing. (Specific outcomes not detailed, but implied to be comparable to predicate's known performance) |
Intended Use and Indications for Use | Similar to the predicate device, for filling bony voids or defects of the skeletal system (extremities, pelvis) that may be surgically created or osseous defects from traumatic injury, only for bony voids or defects not intrinsic to the stability of the bony structure. |
Sterility and Prescription Use | Provided packaged sterile and intended as prescription use only single use devices, consistent with the predicate. |
2. Sample Size Used for the Test Set and Data Provenance
- Sample Size for Test Set: Not explicitly stated for any of the non-clinical tests (chemical, physical, mechanical, biocompatibility, animal testing). The nature of these tests often involves specific numbers of samples per test type (e.g., a certain number of specimens for mechanical strength tests, a certain number of animals for animal studies), but these numbers are not detailed in the summary.
- Data Provenance: The data provenance is internal to Vivorté, Inc. or its contracted laboratories that performed the non-clinical tests. The document does not specify the country of origin for the data, but since the submission is to the U.S. FDA, it is presumed to be conducted under U.S. or internationally recognized standards for and applicable to the U.S. market. All testing described is non-clinical.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications
This question is not applicable as the submission relies solely on non-clinical testing for substantial equivalence, not on human expert evaluation of clinical data or images. Ground truth, in this context, would be established by validated laboratory assays, animal observations, and engineering measurements, not by expert consensus on patient data.
4. Adjudication Method for the Test Set
This question is not applicable for the same reasons as #3. There was no clinical test set requiring human adjudication.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done
No, a Multi-Reader Multi-Case (MRMC) comparative effectiveness study was not done. The document explicitly states: "Clinical testing was not necessary to determine substantial equivalence between Vivorté BVF™ Lite™ and the predicate device" and "No clinical tests were conducted or submitted in support of substantial equivalency." Therefore, there is no effect size of how much human readers improve with AI vs without AI assistance to report, as there was no clinical study involving human readers or AI.
6. If a Standalone (i.e. algorithm only without human-in-the-loop performance) Was Done
This question is not applicable. Vivorté BVF™ Lite™ is a physical medical device (bone void filler), not an algorithm or AI software, so standalone performance in the context of AI is irrelevant.
7. The Type of Ground Truth Used
The ground truth for the non-clinical testing would be derived from:
- Reference Standards/Validated Methods: For chemical composition, physical properties (e.g., density, porosity), and mechanical properties (e.g., compressive strength, bending strength), performance is measured against established scientific and engineering reference standards and/or the known properties of the predicate device.
- Biocompatibility Benchmarks: For biocompatibility and toxicity, the ground truth is established by adherence to recognized international standards (ISO 10993) and national standards (ASTM, USP).
- Animal Study Observations: For animal testing, the ground truth would be based on histological examination, imaging, and gross observations of bone formation, resorption, and overall tissue response in a controlled biological environment, compared to either (or both) untreated controls or the predicate device.
8. The Sample Size for the Training Set
This question is not applicable. As a physical medical device and not an AI/ML algorithm, there is no "training set" in the computational sense. The "knowledge base" for developing the device would stem from scientific literature, material science research, and established medical device development practices.
9. How the Ground Truth for the Training Set Was Established
This question is not applicable for the same reasons as #8.
Ask a specific question about this device
Page 1 of 1